PCV91 HEALTH CARE RESOURCE UTILIZATION AMONG ADULTS WITH TYPE 2 DIABETES MELLITUS, HYPERTENSION, AND OBESITY  by Grandy, S & Fox, KM
Abstracts A167
Subsequent probabilistic analyses will be used to further explore uncertainties around 
the estimates.
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OBJECTIVES: Individuals with type 2 diabetes mellitus (T2DM) utilize more health 
care resources than those without diabetes, yet a portion of the increased use may be 
due to comorbid conditions. This study compared health care resource utilization 
among adults with T2DM plus hypertension (HTN) and obesity with those with 
T2DM only. METHODS: Respondents to the Study to Help Improve Early evaluation 
and management of risk factors Leading to Diabetes (SHIELD), a large US survey, 
self-reported their height, weight, comorbid conditions, number of hospitalizations, 
emergency department (ED) visits, and physician visits in the past 12 months. Respon-
dents reporting T2DM and HTN and obesity (body mass index [BMI] ≥30 kg/m2) 
were identiﬁed and compared with a T2DM-only group. RESULTS: T2DM respon-
dents with, comorbid HTN, and obesity (n = 1186), were younger, more likely to be 
men, and had lower income but were similar to T2DM-only respondents (n = 293) in 
race, education, smoking, and cardiovascular disease history. Respondents with 
T2DM, HTN, and obesity had signiﬁcantly more physician visits (mean of 8 vs. 6, p 
= 0.001), especially 10 or more visits (21% vs. 15%), than respondents with T2DM 
only (p = 0.03). No signiﬁcant differences (p > 0.05) were reported for percentage 
hospitalized (21% vs. 20%) and number of days hospitalized (mean of 7 vs. 11 days) 
over the past 12 months. Respondents with comorbid HTN and obesity reported 
signiﬁcantly more ED visits (9% with 2–13 visits) compared with T2DM-only group 
(5% with 2–5 visits, p = 0.02). CONCLUSIONS: Respondents with comorbid condi-
tions of T2DM, HTN, and obesity have greater health care resource utilization in 
physician ofﬁce visits and ED visits than those with T2DM only.
PCV92
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OBJECTIVES: Resource utilisation data were collected in all three Dabigatran etexi-
late (DBG) Phase III primary VTE prevention following orthopaedic surgery studies. 
This study aimed to, within trial, summarise resource use by treatment group and 
compare resource use separately for each dose of orally-administered DBG (150 mg 
od, 220 mg od) versus subcutaneous enoxaparin. METHODS: The RE-MOBILIZE 
study included 2596 knee-surgery patients and compared DBG to enoxaparin 30 mg 
bid. The RE-MODEL and RE-NOVATE studies included 2076 and 3463 patients 
undergoing knee and hip surgery respectively, and compared DBG with enoxaparin 
40 mg od. All studies used a randomised, double-blind, double-dummy non-inferiority 
design. Duration of treatment differed by study. Data collected for all patients included 
hospitalisation (main and re-admission), non-protocoled diagnostics, blood transfu-
sions, reoperations, concomitant medications and health care contacts for enoxaparin 
injections. Each resource use category was summarised, separately for each study, by 
and between treatment using means and standard errors. Two sample t-tests were used 
to examine differences between treatments. RESULTS: There were no consistently 
signiﬁcant differences between treatments (within each study). The percentages of 
patients requiring domiciliary nurse visits to administer thromboprophylaxis following 
discharge from hospital (i.e. administer subcutaneous enoxaparin or placebo because 
the patient was unable to self-inject) were 5.6% (DBG 150 mg od), 5.0% (DBG 
220 mg od) and 5.4% (enoxaparin) in RE-MOBILIZE, 1.0%, 1.5% and 1.9% in 
RE-MODEL, and 4.4%, 5.1% and 5.0% in RE-NOVATE. All domiciliary nurse visit 
comparisons for each DBG arm versus enoxaparin were statistically non-signiﬁcant 
(P > 0.15). CONCLUSIONS: Double-blind, double-dummy study designs appear to 
be unhelpful in the identiﬁcation of differences that might arise from changes in treat-
ment formulation and route of administration. In this study, a hypothesised difference 
in domiciliary nurse treatment administrations remained undetected due to the double-
dummy nature of the trials.
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OBJECTIVES: Efﬁcient facility operation is an important factor in quality of care for 
hospitals. How treatment protocols inﬂuences efﬁciency and productivity of a cardiac 
hospital is little known. METHODS: A discrete event simulation model of a cardiac 
hospital with percutaneous coronary intervention (PCI) capability was built on analy-
sis of time-stamped electronic medical record database (Cerner Health Facts®). Addi-
tional data were obtained from PCI literature, TRITON TIMI-38 trial, hospital 
statistics, and expert opinions. ACS treatment options include PCI, coronary arterial 
bypass graft (CABG), or drug therapy. Three oral antiplatelet dosing strategies for 
unstable angina (UA) and non-ST segment myocardial infarction (NSTEMI) were 
considered with loading dose given at PCI, minimum 2 hours prior, and minimum 6 
hours prior to PCI. Facility occupancy, wait, PCI volume, and length of stay, were 
tracked. RESULTS: Pre-treatment strategy increased patients’ total time in the hospital 
for all ACS-PCI, with an average time of 114.96 hours with loading dose at PCI, 
118.32 hours (+2.92%) with minimum 2 hours prior, and 121.68 hours (+5.85%) 
with minimum 6 hours prior. For UA/NSTEMI subgroup, total time in hospital was 
129.04 hours with loading at PCI, 134.51 hours (+4.24%) with minimum 2 hours 
prior, and 140.38 hours (+8.79%) with minimum 6 hours prior to PCI. Increase was 
mainly in pre-procedure time. Pre-treatment has no signiﬁcant effect on procedure 
times. Among the CABG-bound patients, pre-operation times increased by 33.49 
hours (+85.77%) and 35.47 hours (+90.83%) under 2 and 6 hour pre-treatment 
strategy, respectively. CONCLUSIONS: Pretreatment strategy with oral antiplatelet is 
likely to cause some inefﬁciency in hospital due to waits and longer total stay. This 
may increase facility congestion, occupancy, and staff hours. In CABG-bound patients, 
pretreatment leads to additional days due to recommended wait. The pretreatment 
strategy as a way to optimize antiplatelet therapy in ACS-PCI entails efﬁciency costs.
CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: To evaluate the level of agreement among three previously validated 
self-reported medication adherence measures and count of tablets records METHODS: 
This was a cross-sectional study which included adult patients (40 and older) with 
hypertension disease enrolled continuously for 6 months in a private medical center. 
Random sequences of tests (communication of self-compliance (SC), Morinsky-Green 
Test (MG) and knowledge of the illness (KI)) were used to estimate the adherence of 
antihypertensive medication. Threshold of 80% was used to determine adherence with 
count of tablets. Concordances were assessed using Cohen’s kappa coefﬁcient (k) and 
prevalence-adjusted bias-adjusted kappa (PABAK). RESULTS: A total of 151 hyper-
tensive patients were included in the study. A total of 65.5% of these patients have 
other comorbilities and 45.6% took more than 5 drugs per day. The prevalence of 
non adherence, using a tablet count as reference test, was 8%. Due substantial imbal-
ance in the fourfold table’s marginal totals we found high agreement of negative results 
(SC (0, 94), MG (0.60), KI (0.72)) but low Kappa (SC (k:- 0,03), MG (k: 0,06), KI 
(k:−0,01)).The Kappa values adjusted (PABAK) were SC (k:0.79), MG (k: −0,06), KI 
(k:0,15). CONCLUSIONS: Because of the weak to moderate concordance found 
among validated measures of adherence, the selection of a useful adherence measure 
in clinical practice is difﬁcult. These ﬁndings underscore the difﬁculty in both assessing 
patients’ medication-taking behavior and assessing and comparing the results of adher-
ence research. The development of valid and reliable measures for easily assessing 
medication adherence behavior in clinical setting is needed.
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OBJECTIVES: To develop predictive models for medication compliance in dyslipid-
emia that will aid health care decision makers in targeting compliance intervention 
programs. METHODS: Pharmacy and medical claims data from a commercial health 
plan were analyzed for all currently enrolled members who received their ﬁrst dyslip-
idemic medication between May 1, 2007 and April 30, 2008. Percentage of days 
covered (PDC) deﬁned as days supply of dyslipidemic medication per 365 days. PDC 
< 80% was used to categorize non-compliant patients. Potential independent variables 
included patient demographics, pharmacy utilization and medical conditions. Stepwise 
logistic regression was used to predict the odds of non-compliance. RESULTS: A total 
of 88,635 patients were included. Sixty-ﬁve percent of patients were non-compliant 
(PDC = 0.33; SD = 0.22). The most signiﬁcant predictor of non-compliance was treat-
ment with bile acid sequestrants (OR: 6.75; p < 0.0001, compared to statins). Signiﬁ-
cant predictors of non-compliance also included age category, increasing from an OR 
= 1.11 for age 45–55 to OR = 3.23 for age <18 [p < 0.0001 for all estimates compared 
to age 75+]; prior diabetes diagnosis (OR: 1.15, p < 0.0001) and the number of unique 
pharmacies used (OR = 1.10 per additional pharmacy; p < 0.0001). Factors reducing 
non-compliance include male gender (OR: 0.77, p < 0.0001); previous heart attack 
(OR: 0.82; p = 0.0221); prior compliant behavior (OR: 0.888; p < 0.0001); number 
of unique physicians seen for medications (OR: 0.969 per additional physician; p < 
0.0001) and copayment categories (relative to no copayment). Compliance signiﬁ-
cantly improved by 12%, 12% and 6% for copay categories $5–$10, $10–$20, and 
$20–$30, respectively to no copayment. (p < 0.01). CONCLUSIONS: The results may 
